{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-26-000004","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.889880+00:00","generated_at":"2026-05-16T11:36:24.752388+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead reports Phase 1/2a data: ARO-INHBE + tirzepatide doubles weight loss in obese T2DM patients","bullets":["ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.","ARO-INHBE monotherapy: single dose reduced visceral fat -9.9% at week 16; two doses gave -15.6% placebo-adjusted at week 24.","ARO-ALK7 is first RNAi to silence an adipocyte gene; mean ALK7 mRNA reduction -88% at 200 mg; visceral fat -14.1% at week 8.","Both candidates generally well tolerated; no discontinuations; one unrelated SAE (limb abscess) in ARO-INHBE group.","Company expects additional results from these ongoing Phase 1/2a studies later in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-26-000004","json":"https://secwatch.observer/filing/0000879407-26-000004.json","markdown":"https://secwatch.observer/filing/0000879407-26-000004.md","text":"https://secwatch.observer/filing/0000879407-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000004/0000879407-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000004/arwr-20260106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:36:24.752388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}